TFBS Bioscience Inc.
TFBS Bioscience Inc., a contract research organization, provides biological testing services in Taiwan. It offers viral vector manufacturing services for cell and gene therapy products; and biosafety testing and product release testing for cell and gene therapy products, vaccines, and biologic products. The company was incorporated in 2016 and is headquartered in New Taipei City, Taiwan.
TFBS Bioscience Inc. (6939) - Net Assets
Latest net assets as of June 2025: NT$1.19 Billion TWD
Based on the latest financial reports, TFBS Bioscience Inc. (6939) has net assets worth NT$1.19 Billion TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.52 Billion) and total liabilities (NT$328.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.19 Billion |
| % of Total Assets | 78.42% |
| Annual Growth Rate | 49.32% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 78.21 |
TFBS Bioscience Inc. - Net Assets Trend (2020–2024)
This chart illustrates how TFBS Bioscience Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for TFBS Bioscience Inc. (2020–2024)
The table below shows the annual net assets of TFBS Bioscience Inc. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.23 Billion | -2.21% |
| 2023-12-31 | NT$1.26 Billion | +1.89% |
| 2022-12-31 | NT$1.24 Billion | +191.20% |
| 2021-12-31 | NT$424.86 Million | +71.35% |
| 2020-12-31 | NT$247.95 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to TFBS Bioscience Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1130.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$349.22 Million | 28.33% |
| Other Components | NT$903.85 Million | 73.32% |
| Total Equity | NT$1.23 Billion | 100.00% |
TFBS Bioscience Inc. Competitors by Market Cap
The table below lists competitors of TFBS Bioscience Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KENYA ORCHARDS LTD
XNAI:KOL
|
$5.40K |
|
BIO-GATE
MU:BIG1
|
$5.40K |
|
Architectural Aesthetics Global Development CO.,LTD.
TWO:2724
|
$5.41K |
|
Enermax Technology Corporation
TWO:8093
|
$5.41K |
|
Agritek Holdings Inc
PINK:AGTK
|
$5.39K |
|
Fat Prophets Global Property Fund
AU:FPP
|
$5.39K |
|
Psyence Biomedical Ltd. Warrant
NASDAQ:PBMWW
|
$5.39K |
|
UET UTD ELECTR - Dusseldorf Stock Exchang
DU:CFC
|
$5.38K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TFBS Bioscience Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,260,606,000 to 1,232,722,000, a change of -27,884,000 (-2.2%).
- Net loss of 38,673,000 reduced equity.
- Dividend payments of 1,740,000 reduced retained earnings.
- New share issuances of 2,682,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-38.67 Million | -3.14% |
| Dividends Paid | NT$1.74 Million | -0.14% |
| Share Issuances | NT$2.68 Million | +0.22% |
| Other Changes | NT$9.85 Million | +0.8% |
| Total Change | NT$- | -2.21% |
Book Value vs Market Value Analysis
This analysis compares TFBS Bioscience Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.54x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.68x to 0.54x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | NT$7.13 | NT$19.10 | x |
| 2021-12-31 | NT$12.21 | NT$19.10 | x |
| 2022-12-31 | NT$35.56 | NT$19.10 | x |
| 2023-12-31 | NT$35.95 | NT$19.10 | x |
| 2024-12-31 | NT$35.43 | NT$19.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TFBS Bioscience Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -21.42%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 1.22x
- Recent ROE (-3.14%) is below the historical average (0.21%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.12% | 0.25% | 0.41x | 1.16x | NT$-24.50 Million |
| 2021 | 1.44% | 3.81% | 0.33x | 1.16x | NT$-36.36 Million |
| 2022 | 2.24% | 10.96% | 0.19x | 1.10x | NT$-96.03 Million |
| 2023 | 0.39% | 2.12% | 0.16x | 1.15x | NT$-121.15 Million |
| 2024 | -3.14% | -21.42% | 0.12x | 1.22x | NT$-161.95 Million |
Industry Comparison
This section compares TFBS Bioscience Inc.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $528,083,167
- Average return on equity (ROE) among peers: 1.54%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TFBS Bioscience Inc. (6939) | NT$1.19 Billion | 0.12% | 0.28x | $5.40K |
| Bionet (1784) | $1.32 Billion | 2.02% | 0.36x | $107.18 Million |
| DIVA Laboratories Ltd (4153) | $1.02 Billion | 4.89% | 0.23x | $25.67 Million |
| Kim Forest Enterprise Co., Ltd. (6645) | $32.49 Million | 0.00% | 7.10x | $20.40 Million |
| Welgene Biotech Co.Ltd. (6661) | $246.55 Million | 11.49% | 0.47x | $3.31 Million |
| Puriblood Medical Co., Ltd. (6847) | $175.40 Million | -3.06% | 0.48x | $13.28 Million |
| Pharmigene, Inc. (7595) | $382.22 Million | -6.13% | 0.10x | $10.10 Million |